In this study the authors investigated whether dysregulation of the fragile X mental retardation protein and mammalian target of rapamycin signaling cascade can have a role in the pathogenesis of encephalopathy of prematurity following perinatal hypoxiaischemia. The authors examined the brain tissue of newborns with encephalopathy and compared it to age-matched controls with normal brain development and adults. In normal controls, the fragile X mental retardation protein expression in cortical gray matter spiked 4-fold during 36-39 gestational weeks compared to the adult, with a concomitant suppression of p70S6K and S6. In encephalopathy cases, the developmental spike of fragile X mental retardation protein was not observed, and fragile X mental retardation protein levels remained significantly lower than in normal controls. Importantly, this fragile X mental retardation protein downregulation was followed by a significant overexpression of p70S6K and S6. These novel findings thus suggest that premature hypoxic-ischemic brain injury can affect the fragile X mental retardation protein/mammalian target of rapamycin pathway, as otherwise observed in inherited syndromes of cognitive disability and autism spectrum disorders.
Brain injury caused by hypoxia-ischemia in premature infants is of enormous public health importance due to the large number of survivors with serious neurocognitive deficits and cerebral palsy. 1, 2 In the United States, approximately 63 000 infants are born annually with a very low birth weight ( 1500 g). This represents 1.5% of all live births, and the importance of encephalopathy in this large group is indicated by the subsequent occurrence of cognitive, behavioral, attention, or socialization deficits in 25-50% of them, and of major motor deficits (eg, cerebral palsy) in 5-10% of them. [1] [2] [3] Encephalopathy of prematurity is a form of cerebral injury that occurs in the setting of either primary or secondary hypoxia-ischemia in the premature infant. 1, 2 Previously, it has been shown in the rat model of encephalopathy of prematurity that white matter is selectively vulnerable to hypoxia-ischemia in the first postnatal week, 4 while similar insults in the second postnatal week cause neocortical strokes and seizures. 5 Hypoxia-ischemia results in excess of extracellular glutamate where excessive activation of receptors can induce ''excitotoxicity'' via their locations on neurons as well as on glia. 4, 5 Glutamatergic excitotoxicity in white matter oligodendrocytes mediated by AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) glutamate receptors was identified as an important factor in this injury. 4, 5 The neuropathological correlates of encephalopathy of prematurity include various lesions, most importantly periventricular leukomalacia, and accompanying neuronal/axonal deficits that involve the cerebral white matter, thalamus, basal ganglia, cerebral cortex, brainstem, and cerebellum. 1 In addition, premature birth further increases the risk of autism spectrum disorders in patients without known autism-related genetic mutations. 3 A recent epidemiological report singles out hypoxia at birth as the only risk factor significantly more prevalent in older mothers of the children with autism spectrum disorders compared to younger mothers. 6 Given the phenotypic overlap between encephalopathy of prematurity and autism spectrum disorders, the authors postulated that perinatal hypoxic-ischemic brain injury might affect the control pathway containing the FMR1 gene implicated in Fragile X syndrome. Fragile X syndrome is the most common inherited cause of intellectual disability with concomitant autism spectrum disorders in 30% cases, comprising for up to 6% of all diagnosed cases of autism. 3, 7 It is typically caused by a trinucleotide repeat expansion of the FMR1 gene leading to its reduced or absent transcription with consequent decreased reduction in translation of the FMR1 protein. 3, 7 Activity-dependent dendritic messenger ribonucleic acid (RNA) translation is normally modulated by FMR1 protein, which usually acts together with multiple other signaling proteins inhibiting the translation of various genes that affect synaptic plasticity. 7, 8 Not surprisingly, FMR1 protein levels were therefore found to correlate with the level of clinical consequences including structural, functional and cognitive brain involvement. 8 Relevant to encephalopathy of prematurity, FMR1 protein-controlled signaling pathways were shown to be upregulated by hypoxic-ischemic brain injury in wild type rodents, in part via overactivation of ionotropic and metabotropic glutamate receptors (mGluRs). 9 The mammalian target of rapamycin signaling cascade, one of FMR1 protein downstream effectors, has been in particular recognized as a central regulator of translation critically needed in developing neurons for establishing synaptic basis for higher order brain functions. 9, 10 Notably, the mammalian target of rapamycin substrate p70S6K can regulate messenger RNA-binding activity of FMR1 protein, while Fmr1 knockout (KO) mice exhibit enhanced activation of mammalian target of rapamycin pathway and display behavioral phenotype similar to patients with autism spectrum disorders. 9, 10 Corresponding molecular and behavioral observations have also been reported by the authors' group in a rodent model of encephalopathy of prematurity. 7 Nonetheless, while oxidative stress and metabotropic glutamate receptors have been shown to play a major role in the pathogenesis of encephalopathy of prematurity and other cerebral disorders, [11] [12] [13] the role of FMR1 protein expressed in perinatal brain tissue following hypoxic-ischemic injury remains undefined. Aiming to fill that gap in this pilot study, the authors have evaluated developmental expression of FMR1 protein and mammalian target of rapamycin substrates p70S6K and S6 in normal human brain and compared it with the expression patterns in brains of premature patients with encephalopathy of prematurity.
Materials and Methods

Human Brain Tissue Specimens
In this pilot study, the authors have used snap frozen and formalin fixed/paraffin embedded tissue from newborns with normal brain development at different ages (20-39 gestational weeks) (n ¼ 15); age-matched newborns with premature hypoxic-ischemic brain injury (ie, encephalopathy of prematurity) (n ¼ 11) and adult controls (n ¼ 4) collected from the Department of Pathology at Children's Hospital Boston, MA; University of Maryland Brain and Tissue Bank, Baltimore, MD and Brigham and Women's Hospital, Boston, MA (adult controls only). The fetuses and infants have died due to prematurity or other disease processes (Table 1) . Only tissues with short postmortem intervals (generally < 24 hours) have been retained and reviewed by a board certified neuropathologist (ML) for diagnostic purposes, and for tissue quality control. Approval of the institutional clinical research committee was obtained. The autopsy permits had also provided parental consent for research. All clinicopathological information was held strictly confidential. Specimens were identified by a random number (not autopsy or medical record number) throughout their processing and analysis. Effort was made to obtain tissue from both genders and from minorities.
Histological Analysis and Immunohistochemical Methods
Standard histological and immunohistochemical procedures, including semiquantitative analyses were performed as previously published. [14] [15] [16] Representative sections of parietal cortex and white matter were stained by hematoxylin and eosin and/or immunohistochemical labeling for total FMR1 protein and phospho-S6 (Ser 235/236 ). To avoid subjectivity in the scoring, a pathologist (ML) performed all histological and immunohistochemical evaluations in a blinded fashion.
Antibodies
The following antibodies have been used for immunohistochemical and immunofluorescence procedures: (1) an anti-phospho-S6 ribosomal protein (Ser 235/236 ) rabbit polyclonal antibody (cat no. 2211, 1:200, Cell Signaling, Boston, MA), (2) an anti-FMR1 protein rabbit polyclonal antibody (Ab17722, 1:5000, Abcam, Cambridge, MA), (3) an anti-GFAP mouse monoclonal antibody (M0761, prediluted, Dako, An Agilent Technologies, Carpinteria, CA), (4) an anti-OLIG2 mouse monoclonal antibody (MABN50, 1:100, EMD Millipore, Billerica, MA), and (5) an anti-metabotropic glutamate receptors mouse monoclonal antibody (MABN540, 1:100, EMD Millipore, Billerica, MA). 
Western Blot Analyses
Statistical Analysis
One-way ANOVA and 2-tailed t-tests were used for multiple comparisons across different developmental ages, or between different development and encephalopathy of prematurity groups. Statistical significance was defined as P < .05.
Results
Developmental Expression of FMR1 protein in Normal Human Brain
To investigate the role of FMR1 protein in premature hypoxicischemic brain injury (ie, encephalopathy of prematurity), the authors first had to map its developmental expression in the normal human brain, a research endeavor that to the authors' knowledge has never been done before. For that purpose, the authors analyzed 15 human postmortem specimens at different stages of normal cortical development, that is, spanning 20-39 gestational weeks. Western blot analyses show a relatively even baseline expression of the total FMR1 protein and phospho-FMR1 protein over 20-35 gestational weeks, which did not differ from the levels observed in normal adult brains ( Figure 1A) . As corroborated by semiquantitative immunohistochemical analysis, baseline cortical levels of the total FMR1 protein in these gestational periods also did not differ from their expression in the white matter ( Figure 1B) . However, during the period spanning 36-39 gestational weeks (n ¼ 6), a transient 4-fold spike in expression of both total ( Figure 1A) and phospho-FMR1 protein (quantification not shown) was observed by western blot analysis in cortical gray matter compared to the adult controls (n ¼ 4; P < .0001) but not in the white matter where FMR1 protein expression remained low to moderate between 20-39 gestational weeks ( Figure 1B ).
Dysregulation of Components of FMR1 Protein/ Mammalian Target of Rapamycin Signaling Cascade in Newborns With Encephalopathy of Prematurity
In contrast to newborns with normal human brain development, this developmental spike in the cortical FMR1 protein expression during the 36-39 gestational weeks was not observed in the cases with encephalopathy of prematurity. FMR1 protein levels remained unchanged compared to the adult controls and the earlier gestational periods (23-35 gestational weeks ( Figure  1C) . A semiquantitative immunohistochemical scoring in cases with encephalopathy of prematurity also showed a 2-fold increase in FMR1 protein expression predominantly in subplate neurons and the white matter compared to normal human brain development during 23-37 gestational weeks, without coexpression in astrocytes and oligodendrocytes ( Figure 1D ). Observed cortical downregulation of the total FMR1 protein and phospho-FMR1 protein in newborns with encephalopathy of prematurity during the 36-39 gestational weeks relative to the newborns with normal human brain development (Figure 2A ; P < .0001) was followed by an overexpression of p70S6K and phospho-p70S6K compared to the normal age-matched controls ( Figure 2B ; P < .0001). In addition, immunohistochemical analysis for pS6 expression in 4 available cases with encephalopathy of prematurity (36-38 gestational weeks) yielded positive staining in subpopulation of cortical neurons and the white matter compared to no expression in nonaffected newborns with normal development during the same gestational period (Figure 3 ).
Coexpression of metabotropic glutamate receptor 5 with the components of FMR1 protein/mammalian target of rapamycin signaling cascade in newborns with encephalopathy of prematurity
To provide some human target validation of the coexpression of the components of the FMR1 protein/mammalian target of rapamycin signaling cascade and metabotropic glutamate receptors the authors have performed fluorescent double labeling with metabotropic glutamate receptor 5 antibody in 4 available cases with encephalopathy of prematurity (36-38 gestational weeks). The analysis has confirmed that metabotropic glutamate receptor 5 was indeed invariably coexpressed with both FMR1 protein ( Figure 4A ) and pS6 ( Figure 4B ) on neurons of the patients with hypoxic-ischemic brain injury.
Discussion
Results presented here demonstrate overexpression of cortical FMR1 protein in 36-39 gestational weeks developmental window, suggesting that FMR1 protein has a physiological role in translation modulation of genes that affect synaptic plasticity in this particular period. 7, 8 These results also confirm that 36-39 gestational weeks is a critical period of development for the brain, providing some explanations why even late preterm newborns are still at risk for abnormal neurodevelopment. 17, 18 In contrast, newborns with encephalopathy of prematurity presented downregulation of FMR1 protein and concomitant overexpression of the mammalian target of rapamycin downstream targets in this critical developmental period. Observed enhanced activation of all investigated components of the mammalian target of rapamycin signaling pathway with concomitant downregulation of FMR1 protein and phospho-FMR1 protein in patients with encephalopathy of prematurity during the 36-39 gestational weeks closely resembles molecular expressions previously reported in FMR1 KO mice. 10 The activation of the mammalian target of rapamycin signaling cascade is known to contribute to normal neuronal growth by promoting their differentiation, neurite elongation and branching, and synaptic formation during development. 19 However, any interruption in normal physiological processes can have consequences on brain development. As shown previously, excess activation of mammalian target of rapamycin signaling causes abnormal development of neurons and glia, leading to brain malformation. 19 In the context of the authors' experiments, these novel observations suggest that one of the mechanisms by which premature hypoxic-ischemic brain injury can cause its long-term sequelae is via dysregulation of signaling pathways otherwise implicated in syndromes of inherited intellectual disability and autism (eg, fragile X syndrome and tuberous sclerosis). 3, 7 While the mechanisms of the premature brain injury and encephalopathy of prematurity are multifactorial, hypoxiaischemia is known to cause increased accumulation of extracellular glutamate, which initiates excitotoxic injury and cell death. 11 Results presented here show coexpression of metabotropic glutamate receptor 5 with both FMR1 protein and pS6 on neurons of patients with encephalopathy of prematurity during the 36-39 gestational weeks, consistent with its reported expression in the brain. 20 In addition, the authors' group recently reported that both metabotropic glutamate receptor 1 and metabotropic glutamate receptor 5 are localized on immature oligodendrocytes throughout human brain development, with metabotropic glutamate receptor 5 being highest in the preterm period. 12 These findings indicate that group I metabotropic glutamate receptors are highly expressed on oligodendrocytes during the peak period of vulnerability to hypoxia-ischemia. 12 Combined, these results are consistent with the proposed metabotropic glutamate receptor theory of pathogenesis in fragile X syndrome suggesting that neurocognitive deficits are related to upregulation of the downstream effectors of the metabotropic glutamate receptor 5 pathway in the cortex and hippocampus. 10 These include phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin signaling components, upregulation of which leads to enhanced long-term depression. 13 In addition, the authors have shown increased FMR1 protein expression predominantly in the white matter and subplate neurons of the newborns with encephalopathy of prematurity, compared to newborns with normal human brain development during 25-37 gestational weeks. This observation might be important because synaptic plasticity in critical periods of development requires intact inhibitory circuitry. 21 Subplate neurons have been reported to regulate the molecular machinery required to establish an adult balance of excitation and inhibition in layer 4 of the white matter. 21 Hence, the link between metabotropic glutamate receptors, FMR1 protein and translation in the setting of premature hypoxic-ischemic brain injury is emerging, emphasizing their important roles in synaptogenesis and synaptic plasticity.
Conclusions
Although encephalopathy of prematurity includes various neuronal/axonal deficits, cognitive deficits including elevated rates of hyperactivity and autism spectrum disorders are by far its dominant neurodevelopmental sequelae. 3 Nonetheless, there is still a significant gap in understanding the molecular basis of this complex disorder as well as an unmet need for early identification and treatment of patients at high risk to develop developmental disorders in later life. Novel findings presented here suggest that dysregulation of FMR1 protein/mammalian target of rapamycin pathways can have a role in pathogenesis of encephalopathy of prematurity, as otherwise observed in the most common inherited syndrome of cognitive disability (eg, fragile X syndrome). The FMR1 protein/mammalian target of rapamycin signaling pathway thus might be a possible new molecular target for treatment of encephalopathy of prematurity and its neurocognitive deficits, a hypothesis that warrants further investigation.
